Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.24)
# 1,151
Out of 4,412 analysts
313
Total ratings
39.8%
Success rate
3.14%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Reiterates: Buy | $92 | $49.86 | +84.52% | 19 | Apr 26, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $28 → $25 | $13.69 | +82.62% | 12 | Apr 26, 2024 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $105 | $54.80 | +91.61% | 15 | Apr 26, 2024 | |
| EVO Evotec SE | Maintains: Buy | $14 → $11 | $5.02 | +119.12% | 6 | Apr 25, 2024 | |
| ROIV Roivant Sciences | Reiterates: Buy | $18 | $11.03 | +63.19% | 11 | Apr 22, 2024 | |
| ALKS Alkermes | Reiterates: Neutral | $35 | $24.68 | +41.82% | 9 | Apr 19, 2024 | |
| ARGX argenx SE | Reiterates: Buy | $451 | $372.80 | +20.98% | 23 | Apr 18, 2024 | |
| AEON AEON Biopharma | Reiterates: Buy | $18 | $5.07 | +255.03% | 2 | Apr 17, 2024 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Buy | $27 | $1.41 | +1,821.71% | 11 | Apr 16, 2024 | |
| TRVN Trevena | Maintains: Buy | n/a | $0.39 | - | 5 | Apr 2, 2024 | |
| IRON Disc Medicine | Reiterates: Buy | $70 | $27.55 | +154.08% | 5 | Apr 1, 2024 | |
| DARE Daré Bioscience | Reiterates: Buy | $6 | $0.31 | +1,861.43% | 11 | Apr 1, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $1.5 → $30 | $8.43 | +255.87% | 11 | Mar 25, 2024 | |
| CABA Cabaletta Bio | Maintains: Buy | $25 → $30 | $11.01 | +172.48% | 14 | Mar 22, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $13 → $11 | $2.04 | +439.22% | 16 | Mar 20, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $50 → $60 | $42.12 | +42.45% | 14 | Mar 20, 2024 | |
| SCPH scPharmaceuticals | Reiterates: Buy | $18 | $4.49 | +300.89% | 8 | Mar 14, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $38 | $25.15 | +51.09% | 13 | Mar 11, 2024 | |
| EOLS Evolus | Reiterates: Buy | $27 | $11.43 | +136.22% | 12 | Mar 8, 2024 | |
| RZLT Rezolute | Reiterates: Buy | $14 | $2.66 | +426.32% | 8 | Mar 7, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | $50 → $63 | $38.97 | +61.66% | 6 | Mar 4, 2024 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $37 | $12.88 | +187.27% | 8 | Feb 29, 2024 | |
| RVNC Revance Therapeutics | Reiterates: Buy | $12 | $3.40 | +252.94% | 16 | Feb 29, 2024 | |
| NERV Minerva Neurosciences | Reiterates: Neutral | $11 | $2.44 | +351.47% | 7 | Feb 27, 2024 | |
| IMVT Immunovant | Maintains: Buy | $47 → $51 | $27.17 | +87.71% | 14 | Dec 21, 2023 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $41 → $45 | $42.47 | +5.96% | 6 | Dec 7, 2023 | |
| TBPH Theravance Biopharma | Reiterates: Buy | $20 | $9.12 | +119.30% | 7 | Aug 8, 2023 | |
| ELYM Eliem Therapeutics | Reiterates: Neutral | $6 | $3.98 | +50.75% | 3 | Mar 8, 2023 | |
| TXMD TherapeuticsMD | Downgrades: Neutral | $10 | $1.86 | +437.63% | 3 | Jun 7, 2022 | |
| HSTO Histogen | Maintains: Buy | $48 → $30 | $0.35 | +8,447.01% | 2 | Mar 29, 2022 | |
| RDUS Radius Health | Maintains: Neutral | n/a | $17.90 | - | 5 | Dec 9, 2021 | |
| DERM Journey Medical | Downgrades: Neutral | n/a | $3.40 | - | 1 | Jan 23, 2020 | |
| ICLR ICON PLC | Maintains: Equal-Weight | n/a | $308.31 | - | 3 | Mar 18, 2019 | |
| TEVA Teva Pharmaceutical | Maintains: Equal-Weight | n/a | $13.81 | - | 5 | Aug 6, 2018 | |
| PCRX Pacira BioSciences | Maintains: Overweight | n/a | $26.33 | - | 1 | Aug 6, 2018 | |
| PAHC Phibro Animal Health | Maintains: Underweight | n/a | $12.73 | - | 1 | Jul 5, 2018 |
Apellis Pharmaceuticals
Apr 26, 2024
Reiterates: Buy
Price Target: $92
Current: $49.86
Upside: +84.52%
Sage Therapeutics
Apr 26, 2024
Maintains: Neutral
Price Target: $28 → $25
Current: $13.69
Upside: +82.62%
Praxis Precision Medicines
Apr 26, 2024
Reiterates: Buy
Price Target: $105
Current: $54.80
Upside: +91.61%
Evotec SE
Apr 25, 2024
Maintains: Buy
Price Target: $14 → $11
Current: $5.02
Upside: +119.12%
Roivant Sciences
Apr 22, 2024
Reiterates: Buy
Price Target: $18
Current: $11.03
Upside: +63.19%
Alkermes
Apr 19, 2024
Reiterates: Neutral
Price Target: $35
Current: $24.68
Upside: +41.82%
argenx SE
Apr 18, 2024
Reiterates: Buy
Price Target: $451
Current: $372.80
Upside: +20.98%
AEON Biopharma
Apr 17, 2024
Reiterates: Buy
Price Target: $18
Current: $5.07
Upside: +255.03%
Marinus Pharmaceuticals
Apr 16, 2024
Reiterates: Buy
Price Target: $27
Current: $1.41
Upside: +1,821.71%
Trevena
Apr 2, 2024
Maintains: Buy
Price Target: n/a
Current: $0.39
Upside: -
Disc Medicine
Apr 1, 2024
Reiterates: Buy
Price Target: $70
Current: $27.55
Upside: +154.08%
Daré Bioscience
Apr 1, 2024
Reiterates: Buy
Price Target: $6
Current: $0.31
Upside: +1,861.43%
Outlook Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $1.5 → $30
Current: $8.43
Upside: +255.87%
Cabaletta Bio
Mar 22, 2024
Maintains: Buy
Price Target: $25 → $30
Current: $11.01
Upside: +172.48%
Coherus BioSciences
Mar 20, 2024
Maintains: Buy
Price Target: $13 → $11
Current: $2.04
Upside: +439.22%
Crinetics Pharmaceuticals
Mar 20, 2024
Maintains: Buy
Price Target: $50 → $60
Current: $42.12
Upside: +42.45%
scPharmaceuticals
Mar 14, 2024
Reiterates: Buy
Price Target: $18
Current: $4.49
Upside: +300.89%
Protagonist Therapeutics
Mar 11, 2024
Maintains: Buy
Price Target: $38
Current: $25.15
Upside: +51.09%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $27
Current: $11.43
Upside: +136.22%
Rezolute
Mar 7, 2024
Reiterates: Buy
Price Target: $14
Current: $2.66
Upside: +426.32%
Biohaven Pharmaceutical Holding Company
Mar 4, 2024
Maintains: Buy
Price Target: $50 → $63
Current: $38.97
Upside: +61.66%
Viridian Therapeutics
Feb 29, 2024
Reiterates: Buy
Price Target: $37
Current: $12.88
Upside: +187.27%
Revance Therapeutics
Feb 29, 2024
Reiterates: Buy
Price Target: $12
Current: $3.40
Upside: +252.94%
Minerva Neurosciences
Feb 27, 2024
Reiterates: Neutral
Price Target: $11
Current: $2.44
Upside: +351.47%
Immunovant
Dec 21, 2023
Maintains: Buy
Price Target: $47 → $51
Current: $27.17
Upside: +87.71%
Cerevel Therapeutics Holdings
Dec 7, 2023
Downgrades: Neutral
Price Target: $41 → $45
Current: $42.47
Upside: +5.96%
Theravance Biopharma
Aug 8, 2023
Reiterates: Buy
Price Target: $20
Current: $9.12
Upside: +119.30%
Eliem Therapeutics
Mar 8, 2023
Reiterates: Neutral
Price Target: $6
Current: $3.98
Upside: +50.75%
TherapeuticsMD
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.86
Upside: +437.63%
Histogen
Mar 29, 2022
Maintains: Buy
Price Target: $48 → $30
Current: $0.35
Upside: +8,447.01%
Radius Health
Dec 9, 2021
Maintains: Neutral
Price Target: n/a
Current: $17.90
Upside: -
Journey Medical
Jan 23, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.40
Upside: -
ICON PLC
Mar 18, 2019
Maintains: Equal-Weight
Price Target: n/a
Current: $308.31
Upside: -
Teva Pharmaceutical
Aug 6, 2018
Maintains: Equal-Weight
Price Target: n/a
Current: $13.81
Upside: -
Pacira BioSciences
Aug 6, 2018
Maintains: Overweight
Price Target: n/a
Current: $26.33
Upside: -
Phibro Animal Health
Jul 5, 2018
Maintains: Underweight
Price Target: n/a
Current: $12.73
Upside: -